Genzyme Canada HomeGenzyme Corporate HomeSearchContact UsGenzyme Websites
Corporate InfoOur Therapies and Products
English  |  Français

Health Care Professionals and Patients:
Research our treatment areas and services for your medical condition and health care practice More >
  Learn about our Canadian operations.  
  Explore opportunities in our entrepreneurial culture.  
  Find out about what is new in our research and development.  
  View a calendar of our events.  
  See what's new for Genzyme in Canada.  


First-of-Its-Kind Treatment for Relapsing-Remitting Multiple Sclerosis Now Available in Canada
Mississauga, ON - Genzyme, a Sanofi company, today announced the Canadian availability of PrLEMTRADA™ (alemtuzumab) for the management of adult patients with relapsing-remitting multiple sclerosis (RRMS), with active disease defined by clinical and imaging features, who have had an inadequate response to interferon beta or other disease-modifying therapies. More>

Health Canada Approves Genzyme’s AUBAGIO® (teriflunomide), a Once-Daily, Oral Treatment for Relapsing Remitting Multiple Sclerosis
Mississauga, ON - Genzyme, a Sanofi company, announced today that Health Canada has approved AUBAGIO® (teriflunomide) 14 mg as monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. More>

Now Aubagio® and Lemtrada® are reimbursed by the RAMQ in Quebec.
Mississauga, ON - October 27, 2014 - Genzyme, a Sanofi company, announces that Aubagio® (teriflunomide) and Lemtrada® (alemtuzumab) have be included on the provincial drug formulary under “Médicaments d’exception”.. More>


Subscribe | Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2015 Genzyme, a Sanofi company. All rights reserved.